Related Experiment Video
Updated: May 1, 2026
Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound 30/45MHZ System
Published on: May 5, 2018
Changes in NT-proBNP in young children with congenital heart malformations
Insights
Serum NT-proBNP levels were significantly elevated in young patients with congenital heart malformations (CHM) before and after surgery. These findings highlight NT-proBNP as a key biomarker for CHM in pediatric congestive heart failure (CHF).
Area of Science:
- Pediatric Cardiology
- Biomarker Discovery
- Congenital Heart Disease
Background:
- Congestive heart failure (CHF) in infants is often secondary to congenital heart malformations (CHM).
- NT-proBNP is a biomarker for cardiac strain, but its role in pediatric CHM requires further investigation.
Purpose of the Study:
- To measure serum NT-proBNP levels in young patients with CHM.
- To compare NT-proBNP levels before and after surgical correction of CHM.
Main Methods:
- Serum NT-proBNP levels were measured in two groups of patients aged 0-36 months with CHM.
- Group 1: 23 patients pre-surgery. Group 2: 12 patients within 24 hours post-surgery.
- NT-proBNP was quantified using ELISA on an automated analyzer.
Main Results:
- NT-proBNP levels were 4 times higher in unoperated CHM patients versus controls (P < 0.001).
- NT-proBNP levels were 12 times higher in post-operative CHM patients versus controls (P = 0.0001).
Conclusions:
- Serum NT-proBNP concentrations show significant elevation in pediatric CHM patients.
- Pre- and post-operative NT-proBNP levels indicate substantial cardiac stress associated with CHM and its surgical correction.
Objective:
We measured serum NT-proBNP levels in 2 groups of young patients (0-36 months) with congestive heart failure (CHF) secondary to congenital heart malformations (CHM).
Methods:
The first group included 23 patients prior to surgery for heart malformations. The second group included 12 patients with CHM within 24 hours post-operation. NT-proBNP levels were measured by an enzyme-linked immunosorbent immunoassay (ELISA) using the Chem Well 2910 (Awareness Technology Inc.) automated analyzer.
Results:
NT-proBNP values were 4 times higher in patients with unoperated CHM compared to healthy controls (P < 0.001), and 12 times higher in patients with CHM 24 hours after surgery compared to controls (P = 0.0001).
Conclusions:
These results demonstrated significant changes in NT-proBNP concentrations before and after surgery to correct congenital heart malformations.
